QCG
KYNB

Quadrant Capital Group’s Kyntra Bio KYNB Stock Holding History

Quadrant Capital Group’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-17
Closed -$7.8K – 2717
2023
Q1 		$7.8K Buy
+17
New +$8.99K ﹤0.01% 2123
2022
Q2 		– Sell
-1
Closed – – 2590
2022
Q1 		$0 Sell
1
-1
-50% -$349 ﹤0.01% 2549
2021
Q4 		$1K Buy
2
+1
+100% +$311 ﹤0.01% 2295
2021
Q3 		$0 Buy
+1
New +$354 ﹤0.01% 2540
2020
Q2 		– Hold
0
– – – 2275
2020
Q1 		– Hold
0
– – – 2157
2019
Q4 		– Sell
-8
Closed -$8.17K – 2436
2019
Q3 		$7K Buy
+8
New +$8.79K ﹤0.01% 1848
2019
Q2 		– Sell
-34
Closed -$45K – 2343
2019
Q1 		$45K Buy
+34
New +$46.1K 0.01% 1279
2016
Q2 		– Sell
-11
Closed -$5K – 2002
2016
Q1 		$5K Buy
+11
New +$5.48K ﹤0.01% 1154

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quadrant Capital Group's KYNB Position: Q2 2023 in Review

Quadrant Capital Group sold out of Kyntra Bio (KYNB) in Q2 2023, closing a stake of 17 shares — an estimated $7.8K sold.

Quadrant Capital Group first reported a position in KYNB in Q1 2016 and held it in 7 quarters. The position peaked at $45K in Q1 2019. 152 funds tracked by Wall St. Rank hold KYNB as of Q2 2023.

  • Quadrant Capital Group reported no remaining Kyntra Bio position as of Q2 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 17 Kyntra Bio shares in Q2 2023, an estimated $7.8K.
  • Quadrant Capital Group first reported a position in Kyntra Bio in Q1 2016 and held it in 7 quarters.
  • Quadrant Capital Group's Kyntra Bio position peaked at $45K in Q1 2019.
  • 152 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2023.

Based on Quadrant Capital Group's 13F filing for Q2 2023, filed 10 Aug 2023.